PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Ovintiv Inc. (OVV)
40.910.33 (-0.80%)
40.40 - 41.05
29.80 - 47.18
2.12M / 3.66M (Avg.)
18.02 | 2.27
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-1.36%
Both firms have declining sales. Martin Whitman would suspect an industry slump or new disruptive entrants.
7.74%
Positive gross profit growth while CVE is negative. John Neff would see a clear operational edge over the competitor.
20.56%
Positive EBIT growth while CVE is negative. John Neff might see a substantial edge in operational management.
20.56%
Positive operating income growth while CVE is negative. John Neff might view this as a competitive edge in operations.
-92.95%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-64.64%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-64.64%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1.96%
Dividend reduction while CVE stands at 0.00%. Joel Greenblatt would question the firm’s cash flow stability or capital allocation decisions.
-62.50%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-708.16%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
-6.27%
Negative 10Y revenue/share CAGR while CVE stands at 122.98%. Joel Greenblatt would question if the company is failing to keep pace with industry changes.
300.94%
5Y revenue/share CAGR above 1.5x CVE's 122.98%. David Dodd would look for consistent product or market expansions fueling outperformance.
-9.00%
Both firms have negative 3Y CAGR. Martin Whitman would wonder if the entire market segment is in short-term retreat.
-67.83%
Negative 10Y OCF/share CAGR while CVE stands at 11.62%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
-80.97%
Negative 5Y OCF/share CAGR while CVE is at 11.62%. Joel Greenblatt would question the firm’s operational model or cost structure.
-76.64%
Both face negative short-term OCF/share growth. Martin Whitman would suspect macro or cyclical issues hitting them both.
-87.90%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
-68.44%
Both exhibit negative net income/share growth over five years. Martin Whitman would suspect a challenging environment for the entire niche.
179.97%
Positive short-term CAGR while CVE is negative. John Neff would see a clear advantage in near-term profit trajectory.
6.74%
10Y equity/share CAGR 1.25-1.5x CVE's 5.16%. Bruce Berkowitz would see if strong ROE or conservative payout policy fosters faster book value growth.
-40.91%
Negative 5Y equity/share growth while CVE is at 5.16%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
-41.05%
Negative 3Y equity/share growth while CVE is at 7.91%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
70.89%
10Y dividend/share CAGR above 1.5x CVE's 26.15%. David Dodd checks if the firm's robust cash flows justify outpacing the competitor's increases.
-66.21%
Negative 5Y dividend/share CAGR while CVE stands at 26.15%. Joel Greenblatt sees a weaker commitment to dividends vs. a competitor that might be growing them.
-66.21%
Negative near-term dividend growth while CVE invests at 32.64%. Joel Greenblatt sees a weaker short-term distribution policy unless justified by strategic spending.
51.21%
Our AR growth while CVE is cutting. John Neff questions if the competitor outperforms in collections or if we’re pushing credit to maintain sales.
No Data
No Data available this quarter, please select a different quarter.
15.41%
Positive asset growth while CVE is shrinking. John Neff sees potential for us to outgrow the competitor if returns are solid.
1.97%
Positive BV/share change while CVE is negative. John Neff sees a clear edge over a competitor losing equity.
15.15%
Debt growth far above CVE's 1.00%. Michael Burry fears the firm is taking on undue leverage vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
-5.69%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.